🏛️ Verified NIH Record • Updated 2026-08-20

Study of ABBV-142 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Idiopathic Pulmonary Fibrosis (NCT07230288)

A Phase 2a Multicenter Platform Study of Investigational Products for the Treatment of Adult Subjects With Idiopathic Pulmonary Fibrosis

🟢 Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: AbbVie

🩺 Plain-English Summary (8th-Grade Level)

Idiopathic Pulmonary Fibrosis (IPF) is a rare, long-lasting lung disease that causes scarring of lung tissue, shortness of breath, and loss of lung function. IPF leads to significant loss of quality of life and shortened lifespan. This study is a platform study evaluating different types of treatments in patients with IPF. A platform study is a type of study that uses a single master protocol to evaluate different study treatments allowing for new study treatments or substudies to be added or closed over time. The main goals of the study are to evaluate the safety, tolerability (the degree to which the adverse symptoms can be handled by the patients during the study) and efficacy (how well study treatment works) of the study treatments, including ABBV-142 in Substudy 1 (SS1). ABBV-142 is an investigational drug being developed for the treatment of IPF. In SS1, participants will be randomly assigned to one of the 2 groups to receive either ABBV-142 or a matching placebo. This study is "double-blind", meaning that neither the participants nor the study doctors know who is given which study treatment. Approximately 165 adult participants with IPF will be enrolled in approximately 125 sites across the world. Participants will receive ABBV-142 or matching placebo for 52 weeks during the double-blind treatment period. Eligible participants may receive ABBV-142 for 52 weeks in open-label treatment period. All participants will be followed for 120 days. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Who can join: Review the eligibility criteria below.

Location: The University of Alabama at Birmingham /ID# 277613 — Birmingham, Alabama

Age range: 40 Years

🧪 Interventions in This Study

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (49 Sites)

Showing the first 25 of 49 sites.

  • The University of Alabama at Birmingham /ID# 277613 — Birmingham, Alabama
  • Sec Clinical Research - East - Dothan - Graceland /ID# 278328 — Dothan, Alabama
  • Clinical Research Specialists - Kissimmee /ID# 279184 — Kissimmee, Florida
  • Christie Clinic on University /ID# 277871 — Champaign, Illinois
  • University of Michigan Health System - Ann Arbor /ID# 279994 — Ann Arbor, Michigan
  • Henry Ford Hospital /ID# 277843 — Detroit, Michigan
  • Hannibal Regional Hospital /ID# 277984 — Hannibal, Missouri
  • Jefferson Health Honickman Center /ID# 279127 — Philadelphia, Pennsylvania
  • Inova Fairfax Hospital /ID# 278469 — Falls Church, Virginia
  • Virginia Commonwealth University Medical Center /ID# 277992 — Richmond, Virginia
  • Lung Research Queensland /ID# 278838 — Nundah, Queensland
  • Box Hill Hospital /ID# 278245 — Melbourne, Victoria
  • University Multiprofile Hospital for Active Treatment Dr. Georgi Stranski /ID# 277845 — Pleven,
  • University Multiprofile Hospital For Active Treatment Sveti Georgi - Plovdiv /ID# 279367 — Plovdiv,
  • Acibadem City Clinic Tokuda University Hospital EAD /ID# 277846 — Sofia,
  • Diagnostic Consultative Center Convex /ID# 277848 — Sofia,
  • Diagnostic Consultative Center Convex /ID# 277849 — Sofia,
  • Centre d'Investigation Clinique Mauricie /ID# 277949 — Trois-Rivières, Quebec
  • Klinikum Konstanz /ID# 278139 — Konstanz, Baden-Wurttemberg
  • Caritas-Krankenhaus St. Maria gGmbH /ID# 278138 — Donaustauf, Bavaria
  • University General Hospital of Patras /ID# 277726 — Pátrai, Achaia
  • General Hospital of Chest Diseases of Athens SOTIRIA /ID# 277724 — Athens, Attica
  • University General Hospital of Heraklion /ID# 277717 — Heraklion, Crete
  • University Hospital of Ioannina /ID# 277719 — Ioannina,
  • General Hospital of Thessaloniki George Papanikolaou /ID# 277819 — Thessaloniki,

📞 Contact the Study Coordinator

Phone: (844) 663-3742

Email: abbvieclinicaltrials@abbvie.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Idiopathic Pulmonary Fibrosis

Explore by condition: All Idiopathic Pulmonary Fibrosis clinical trials

💡 How to Participate

  1. Check the checklist above to see if you may qualify.
  2. Contact the study coordinator using the phone/email above.
  3. Ask about the visit schedule, what is covered at no cost, and any travel support.
  4. Confirm with your own doctor before making a decision.
🏛️ View Official NIH Record ↗